The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia.
Methods
Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months.
Results
The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-α) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study.
Conclusions
MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.
DonohoeC.L., RyanA.M., ReynoldsJ.V.: Cancer cachexia: mechanisms and clinical implications.Gastroenterol Res Pract, 2011: 601434, 2011.
2.
CossC.C., BohlC.E., DaltonJ.T.: Cancer cachexia therapy: a key weapon in the fight against cancer.Curr Opin Clin Nutr Metab Care, 14: 268–273, 2011.
3.
MantovaniG., MadedduC.: Cancer cachexia: medical management.Support Care Cancer, 18: 1–9, 2010.
4.
FearonK.C.: Cancer cachexia: developing multimodal therapy for a multidimensional problem.Eur J Cancer, 44: 1124–1132, 2008.
5.
DeWysW.D., BeggC., LavinP.T., BandP.R., BennettJ.M., BertinoJ.R., CohenM.H., DouglassH.O.Jr., EngstromP.F., EzdinliE.Z., HortonJ., JohnsonG.J., MoertelC.G., OkenM.M., PerliaC., RosenbaumC., SilversteinM.N., SkeelR.T., SponzoR.W., TormeyD.C.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.Am J Med, 69: 491–497, 1980.
6.
BuccheriG., FerrignoD.: Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer.Lung cancer, 34: 433–440, 2001.
7.
HessL.M., BarakatR., TianC., OzolsR.F., AlbertsD.S.: Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol, 107: 260–265, 2007.
8.
BerensteinE.G., OrtizZ.: Megestrol acetate for the treatment of anorexia-cachexia syndrome.Cochrane Database Syst Rev, CD004310, 2005.
9.
MantovaniG., MaccioA., MadedduC., SerpeR., AntoniG., MassaE., DessìM., PanzoneF.: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.J Mol Med, 88: 85–92, 2010.
10.
MurphyR.A., YeungE., MazurakV.C., MourtzakisM.: Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia.Br J Cancer, 105: 1469–1473, 2011.
11.
DavisM.P., YavuzsenT., KirkovaJ., WalshD., KarafaM., LeGrandS., LagmanR.: Validation of a simplified anorexia questionnaire.J Pain Symptom Manage, 38: 691–697, 2009.
12.
ArgilésJ.M., OlivanM., BusquetsS., Lépez-SorianoF.J.: Optimal management of cancer anorexia-cachexia syndrome.Cancer Manag Res, 2: 27–38, 2010.
13.
MantovaniG., MaccioA., MadedduC., SerpeR., MassaE., DessìM., PanzoneF., ContuP.: Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.Oncologist, 15: 200–211, 2010.
14.
MadedduC., DessiM., PanzoneF., SerpeR., AntoniG., CauM.C., MontaldoL., MelaQ., MuraM., AstaraG., TancaF.M., MacciòA., MantovaniG.: Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.Clin Nutr, 31: 176–182, 2012.
15.
Pascual LopezA., Roque i FigulsM., Urrutia CuchiG., BerensteinE.G., Almenar PasiesB., Balcells AlegreM., HerdmanM.: Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.J Pain Symptom Manage, 27: 360–369, 2004.
16.
De ConnoF., MartiniC., ZeccaE., BalzariniA., VenturinoP., GroffL., CaraceniA.: Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial.Eur J Cancer, 34: 1705–1709, 1998.
17.
JatoiA., WindschitlH.E., LoprinziC.L., SloanJ.A., DakhilS.R., MailliardJ.A., PundaleekaS., KardinalC.G., FitchT.R., KrookJ.E., NovotnyP.J., ChristensenB.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.J Clin Oncol, 20: 567–573, 2002.
18.
LoprinziC.L., KuglerJ.W., SloanJ.A., MailliardJ.A., KrookJ.E., WilwerdingM.B., RowlandK.M.Jr., CamorianoJ.K., NovotnyP.J., ChristensenB.J.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.J Clin Oncol, 17: 3299–3306, 1999.
19.
KumarN.B., KaziA., SmithT., CrockerT., YuD., ReichR.R., ReddyK., HastingsS., ExtermanM., BalducciL., DaltonK., BeplerG.: Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.Curr Treat Options Oncol, 11: 107–117, 2010.
20.
HamermanD.: Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia.J Gerontol A Biol Sci Med Sci, 57: M511–518, 2002.
21.
FearonK.C., BarberM.D., MosesA.G., AhmedzaiS.H., TaylorG.S., TisdaleM.J., MurrayG.D.: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.J Clin Oncol, 24: 3401–3407, 2006.
22.
JatoiA., RowlandK., LoprinziC.L., SloanJ.A., DakhilS.R., MacDonaldN., GagnonB., NovotnyP.J., MailliardJ.A., BusheyT.I., NairS., ChristensenB.; North Central Cancer Treatment Group: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.J Clin Oncol, 22: 2469–2476, 2004.
HusseyH.J., TisdaleM.J.: Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.Int J Cancer, 87: 95–100, 2000.
25.
LaiV., GeorgeJ., RicheyL., KimH.J., CannonT., ShoresC., CouchM.: Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.Head Neck, 30: 67–74, 2008.
